Organogenesis (NASDAQ:ORGO) Stock Price Down 1.6% – Should You Sell?

Organogenesis (NASDAQ:ORGO) dropped 1.6% during trading on Friday . The company traded as low as $2.32 and last traded at $2.39. Approximately 1,179,184 shares changed hands during trading, an increase of 51% from the average daily volume of 783,361 shares. The stock had previously closed at $2.43.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. BTIG Research cut shares of Organogenesis from a “buy” rating to a “neutral” rating in a research note on Friday, May 8th. UBS Group set a $3.00 price target on shares of Organogenesis in a research report on Thursday, May 28th. Wall Street Zen raised shares of Organogenesis from a “strong sell” rating to a “sell” rating in a report on Saturday, June 20th. Weiss Ratings downgraded shares of Organogenesis from a “hold (c)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Finally, Truist Financial initiated coverage on shares of Organogenesis in a research report on Thursday, May 28th. They issued a “hold” rating and a $3.00 price objective for the company. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $5.75.

Organogenesis Stock Performance

The company has a quick ratio of 3.16, a current ratio of 3.53 and a debt-to-equity ratio of 0.05. The firm has a 50-day moving average price of $2.47 and a two-hundred day moving average price of $2.88. The firm has a market cap of $307.55 million, a PE ratio of -12.58 and a beta of 1.33.

Organogenesis (NASDAQ:ORGO) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.08). Organogenesis had a positive return on equity of 9.63% and a negative net margin of 0.84%.The firm had revenue of $37.23 million for the quarter, compared to analysts’ expectations of $43.26 million.

Institutional Investors Weigh In On Organogenesis

Hedge funds have recently modified their holdings of the business. SG Americas Securities LLC grew its holdings in Organogenesis by 199.4% in the 4th quarter. SG Americas Securities LLC now owns 565,501 shares of the company’s stock valued at $2,929,000 after buying an additional 376,623 shares in the last quarter. GSA Capital Partners LLP acquired a new position in shares of Organogenesis during the 4th quarter valued at about $992,000. Flax Pond Capital LLC acquired a new stake in Organogenesis during the fourth quarter worth about $2,197,000. Hennion & Walsh Asset Management Inc. raised its stake in Organogenesis by 31.2% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 208,341 shares of the company’s stock worth $1,079,000 after purchasing an additional 49,601 shares during the period. Finally, Caitong International Asset Management Co. Ltd purchased a new position in Organogenesis during the fourth quarter worth about $75,000. 49.57% of the stock is currently owned by institutional investors and hedge funds.

About Organogenesis

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.